EGF and non-small cell lung carcinoma: In Cuba, CIMAvax-EGF is available for use as a maintenance therapy following progression through Phase IV clinical trials in the late 2010s, where patients with advanced NSCLC receiving prior chemotherapy were enrolled, demonstrating safety, reduced EGF in serum, and increased OS [126].